Abstract
Renal artery denervation (RDN) represents a relatively new technique for treating patients whose arterial hypertension persists despite three or more antihypertensive medications [1]. The main principle underlying RDN dates back 50 years or more and gave rise to surgical sympathectomy procedures [2]. Radiofrequency (RF) catheter ablation is a therapeutic procedure that delivers a controlled source of energy in order to create a lesion at the site of the target tissue. Lesion formation is restricted to a limited volume of tissue close to the ablation electrode. Since this technique was first introduced, it has become one of the most useful and widely accepted therapies in the field of cardiac electrophysiology, later followed by application in renal denervation procedures. Modifications in RF delivery and improvements in electrode design have resulted in a significant expansion of its indication such as chronic kidney disease (CKD), arrhythmias, obstructive sleep apnoea and glucose control [3, 4].
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension. 2008;51:1403–19.
Chris SM. Sympathectomy for hypertension. Br Med J. 1951;1:665–70.
Linz D, Hohl M, Nickel A, et al. Effect of renal denervation on neurohumoral activation triggering atrial fibrillation in obstructive sleep apnea. Hypertension. 2013;62:767–74.
Ammar S, Ladich E, Steigerwald K, Deisenhofer I, Joner M. Pathophysiology of renal denervation procedures: from renal nerve anatomy to procedural parameters. EuroIntervention. 2013;9:R89–95.
Kaltenbach B, Id D, Franke JC, et al. Renal artery stenosis after renal sympathetic denervation. J Am Coll Cardiol. 2012;60:2694–5.
Lustgarten DL, Spector PS. Ablation using irrigated radiofrequency: a hands-on guide. Heart Rhythm. 2008;5:899–902.
Haines DE. The biophysics of radiofrequency catheter ablation in the heart: the importance of temperature monitoring. Pacing Clin Electrophysiol. 1993;16:586–91.
Erez A, Shitzer A. Controlled destruction and temperature distributions in biological tissues subjected to monoactive electrocoagulation. J Biomech Eng. 1980;102:42–9.
Ko WC, Huang SK, Lin JL, Shau WY, Lai LP, Chen PH. New method for predicting efficiency of heating by measuring bioimpedance during radiofrequency catheter ablation in humans. J Cardiovasc Electrophysiol. 2001;12:819–23.
Avitall B, Mughal K, Hare J, Helms R, Krum D. The effects of electrode-tissue contact on radiofrequency lesion generation. Pacing Clin Electrophysiol. 1997;20:2899–910.
Otomo K, Yamanashi WS, Tondo C, et al. Why a large tip electrode makes a deeper radiofrequency lesion: effects of increase in electrode cooling and electrode-tissue interface area. J Cardiovasc Electrophysiol. 1998;9:47–54.
Nakagawa H, Yamanashi WS, Pitha JV, et al. Comparison of in vivo tissue temperature profile and lesion geometry for radiofrequency ablation with a saline-irrigated electrode versus temperature control in a canine thigh muscle preparation. Circulation. 1995;91:2264–73.
Krum H, Schlaich MP, Bohm M, et al. Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study. Lancet. 2014;383:622–9.
Worthley SG, Tsioufis CP, Worthley MI, et al. Safety and efficacy of a multi-electrode renal sympathetic denervation system in resistant hypertension: the EnligHTN I trial. Eur Heart J. 2013;34:2132–40.
Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Bohm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (the Symplicity HTN-2 trial): a randomised controlled trial. Lancet. 2010;376:1903–9.
Kandzari DE, Bhatt DL, Sobotka PA, et al. Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 trial. Clin Cardiol. 2012;35:528–35.
Bhatt DL, Kandzari DE, O’Neill WW, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014. doi:10.1056/NEJMoa1402670.
Templin C, Jaguszewski M, Ghadri JR, et al. Vascular lesions induced by renal nerve ablation as assessed by optical coherence tomography: pre- and post-procedural comparison with the simplicity(R) catheter system and the EnligHTN multi-electrode renal denervation catheter. Eur Heart J. 2013;34:2141–8.
Nakagawa H, Wittkampf FH, Yamanashi WS, et al. Inverse relationship between electrode size and lesion size during radiofrequency ablation with active electrode cooling. Circulation. 1998;98:458–65.
d’Avila A, Houghtaling C, Gutierrez P, et al. Catheter ablation of ventricular epicardial tissue: a comparison of standard and cooled-tip radiofrequency energy. Circulation. 2004;109:2363–9.
Sakakura K, Ladich E, Edelman ER, et al. Methodological standardization for the preclinical evaluation of renal sympathetic denervation. JACC Cardiovasc Interv. 2014. doi:10.1016/j.jcin.2014.04.024.
Whitney KM, Schwartz Sterman AJ, O’Connor J, Foley GL, Garman RH. Light microscopic sciatic nerve changes in control beagle dogs from toxicity studies. Toxicol Pathol. 2011;39:835–40.
Burgi K, Cavalleri MT, Alves AS, Britto LR, Antunes VR, Michelini LC. Tyrosine hydroxylase immunoreactivity as indicator of sympathetic activity: simultaneous evaluation in different tissues of hypertensive rats. Am J Physiol Regul Integr Comp Physiol. 2011;300:R264–71.
DiBona GF, Esler M. Translational medicine: the antihypertensive effect of renal denervation. Am J Physiol Regul Integr Comp Physiol. 2010;298:R245–53.
Tellez A, Rousselle S, Palmieri T, et al. Renal artery nerve distribution and density in the porcine model: biologic implications for the development of radiofrequency ablation therapies. Transl Res. 2013;162:381–9.
Ahmed H, Neuzil P, Skoda J, et al. Renal sympathetic denervation using an irrigated radiofrequency ablation catheter for the management of drug-resistant hypertension. JACC Cardiovasc Interv. 2012;5:758–65.
Kiuchi MG, Maia GL, de Queiroz Carreira MA, et al. Effects of renal denervation with a standard irrigated cardiac ablation catheter on blood pressure and renal function in patients with chronic kidney disease and resistant hypertension. Eur Heart J. 2013;34:2114–21.
Remo BF, Preminger M, Bradfield J, et al. Safety and efficacy of renal denervation as a novel treatment for ventricular tachycardia storm in patients with cardiomyopathy. Heart Rhythm. 2013. doi:10.1016/j.hrthm.2013.12.038.
Bertog SC, Sobotka PA, Sievert H. Renal denervation for hypertension. JACC Cardiovasc Interv. 2012;5:249–58.
Mahfoud F, Ewen S, Ukena C, et al. Expanding the indication spectrum: renal denervation in diabetes. EuroIntervention. 2013;9:R117–21.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer-Verlag London
About this chapter
Cite this chapter
Sakakura, K., Ladich, E., Fuimaono, K., Virmani, R., Joner, M. (2015). Radiofrequency and Irrigated Ablation: Principles and Potential for Renal Artery Denervation (RDN) in the Treatment of Resistant Arterial Hypertension. In: Heuser, R., Schlaich, M., Sievert, H. (eds) Renal Denervation. Springer, London. https://doi.org/10.1007/978-1-4471-5223-1_18
Download citation
DOI: https://doi.org/10.1007/978-1-4471-5223-1_18
Published:
Publisher Name: Springer, London
Print ISBN: 978-1-4471-5222-4
Online ISBN: 978-1-4471-5223-1
eBook Packages: MedicineMedicine (R0)